Analysts expect MaxCyte to post earnings of ($0.12) per share and revenue of $6.5060 million for the quarter. MaxCyte (NASDAQ:MXCT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. View Our Latest Research Report on MaxCyteHedge Funds Weigh In On MaxCyteA number of institutional investors and hedge funds have recently made changes to their positions in MXCT. MaxCyte Company Profile(Get Free Report)MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells.